Prostate cancer is a disease that only affects men. It starts in the prostate, a small walnut-shaped gland that produces some of the fluid in semen.
When someone has metastatic castration-resistant prostate cancer (mCRPC), it means the cancer has spread to other parts of the body and it doesn’t respond to treatments that lower testosterone.
The New Prostate Cancer Study
Recently, a group of scientists did a big study on mCRPC. They wanted to see if mixing two medicines, talazoparib and enzalutamide, could help these patients.
The lead scientist was a doctor named Neeraj Agarwal from the University of Utah.
The study involved lots of men who were getting treatment for mCRPC at hospitals and cancer centers in 26 different countries.
The men were randomly chosen to take either talazoparib with enzalutamide or enzalutamide with a placebo, which is a pill that doesn’t do anything.
What the Scientists Found
The results of the study were really promising! The group that took both talazoparib and enzalutamide did not reach what scientists call “radiographic progression-free survival” (rPFS).
This term sounds a little complicated, but it just means that the cancer didn’t get worse when looking at scans of the body.
On the other hand, the group that took enzalutamide with a placebo had an rPFS of 21.9 months. This means that the cancer did not get worse for about 22 months.
Side Effects of the Medicines
Like all medicines, talazoparib and enzalutamide can cause some side effects. The most common ones were feeling tired and having low levels of red and white blood cells.
But most side effects were not too serious and got better when the doctors adjusted the dose of the medicines.
What This Means for the Future
These results are important because they suggest that combining talazoparib and enzalutamide could be a good treatment option for men with mCRPC.
The scientists believe that this medicine mix could become a first-line treatment. This means it could be the first treatment doctors try when they find out someone has mCRPC.
It’s important to note, though, that this study was funded by Pfizer, the company that makes talazoparib and enzalutamide. Some of the scientists also have ties to other pharmaceutical companies.
A Final Word
Studies like these help doctors find better ways to treat diseases. However, just like the superheroes in our previous story, medicine can’t do everything on its own.
A healthy lifestyle, regular check-ups, and following your doctor’s advice are all important for staying healthy.
If you care about prostate health, please read studies that coffee may help lower the risk of prostate cancer, and dairy foods may increase men’s risk of prostate cancer.
For more information about health, please see recent studies that a low-carb diet could increase overall cancer risk, and results showing vitamin D supplements strongly reduce cancer death.
The study was published in The Lancet.
Copyright © 2023 Knowridge Science Report. All rights reserved.
